As President of the Catalytic Impact Foundation since 2018, Rachel has helped to guide the growth of the organization to become a philanthropic leader in deploying catalytic capital to accelerate innovation in underfunded areas of healthcare, where there are significant unmet medical needs. These areas of focus include women’s health, children’s health, rare disease, and brain/mental health. She has extensive experience and expertise analyzing, evaluating, and investing in early- and mid-stage companies in the life sciences and healthcare industry. She regularly speaks on a variety of topics, including alternative funding strategies for early-stage healthcare innovation, impact investing in healthcare, the important role of philanthropic capital, and various topics in women’s health and children’s health.

Previously, Rachel served as Co-Founder and Editor-in-Chief of Asthma Magazine, a patient education publication for asthma and allergy. The magazine was used by the NHLBI in its national children’s asthma (CAMP) study; by Merck to launch its first-in-class asthma drug, Singulair; and by the American Lung Association, the American Academy of Asthma, Allergy and Immunology, the National Association of School Nurses, and private practitioners throughout the country, to educate their patients about the condition. Subsequently, she guided the company through its acquisition by Elsevier Health Sciences, a leading publisher of medical journals, where she continued as Editor-in-Chief.